Literature DB >> 24016283

Late rebound of infantile hemangioma after cessation of oral propranolol.

Nancy Shehata1, Julie Powell, Josée Dubois, Afshin Hatami, Elizabeth Rousseau, Sandra Ondrejchak, Catherine McCuaig.   

Abstract

Propranolol has become the first line of treatment for infantile hemangiomas (IHs), with a high response rate, but rebound growth after cessation of propranolol has been reported, primarily in the first year of life. We sought to determine the frequency and associated factors leading to late regrowth after successful treatment at an age when the proliferative phase has usually ceased. We retrospectively reviewed the clinical charts, serial photographs, and radiologic images of children with rebound IH occurring after the age of 15 months after a successful course of oral propranolol averaging 2.6 mg/kg/day (range 2-3 mg/kg/day). Thirteen (10 female, 3 male) of 212 patients (6%) treated with oral propranolol since 2008 were evaluated. The mean age at the start of treatment was 5.3 months (range 1.8-13 months), and an average of 10.3 months (range 4.5-16 months) of treatment was given. It took an average of 5.3 months (range 1-13.8 months) for a significant rebound to appear. Late rebound after successful propranolol indicates a prolonged proliferation phase of IH even after 15 months of age. This is compared with previous reports of rebound, which occurred primarily in infants younger than 1 year old. Late proliferation can occur in localized, small, mixed, and deep IH, even after several months of a positive response to propranolol. A second course of propranolol readily controlled the recurrence.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24016283     DOI: 10.1111/pde.12190

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  10 in total

1.  Management of periorbital hemangioma by intralesional glucocorticoids and systemic propranolol: a single-center retrospective study.

Authors:  Si-Ming Yuan; Lei Cui; Yao Guo; Chun-Yan Xue; Zhi-Jian Hong; Hui-Qing Jiang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  A retrospective study to classify surgical indications for infantile hemangiomas.

Authors:  Andrew H Y Lee; Krista L Hardy; David Goltsman; Peter Liou; Maria C Garzon; Christine H Rohde; June K Wu
Journal:  J Plast Reconstr Aesthet Surg       Date:  2014-05-16       Impact factor: 2.740

Review 3.  Beta blockers: an innovation in the treatment of infantile hemangiomas.

Authors:  Shehla Admani; Stephanie Feldstein; Ernesto M Gonzalez; Sheila Fallon Friedlander
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

4.  Infantile hemangioma: factors causing recurrence after propranolol treatment.

Authors:  Lei Chang; Dongze Lv; Zhang Yu; Gang Ma; Hanru Ying; Yajing Qiu; Yifei Gu; Yunbo Jin; Hui Chen; Xiaoxi Lin
Journal:  Pediatr Res       Date:  2017-10-11       Impact factor: 3.756

5.  When to stop propranolol for infantile hemangioma.

Authors:  Lei Chang; Yifei Gu; Zhang Yu; Hanru Ying; Yajing Qiu; Gang Ma; Hui Chen; Yunbo Jin; Xiaoxi Lin
Journal:  Sci Rep       Date:  2017-02-22       Impact factor: 4.379

6.  Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.

Authors:  Liuqing Zhu; Jinye Xie; Zhenyin Liu; Zhijian Huang; Mao Huang; Haofan Yin; Weiwei Qi; Zhonghan Yang; Ti Zhou; Guoquan Gao; Jing Zhang; Xia Yang
Journal:  Cancer Sci       Date:  2018-05-23       Impact factor: 6.716

7.  EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT.

Authors:  Jaime Anger; Eduardo Mesquita de Oliveira; José Gabel
Journal:  Rev Paul Pediatr       Date:  2019-05-09

8.  Infantile hemangiomas: risk factors for complications, recurrence and unaesthetic sequelae.

Authors:  Letícia Gaertner Mariani; Lílian Moraes Ferreira; Diego Luiz Rovaris; Renan Rangel Bonamigo; Ana Elisa Kiszewski
Journal:  An Bras Dermatol       Date:  2021-11-27       Impact factor: 1.896

Review 9.  Signaling pathways in the development of infantile hemangioma.

Authors:  Yi Ji; Siyuan Chen; Kai Li; Li Li; Chang Xu; Bo Xiang
Journal:  J Hematol Oncol       Date:  2014-01-31       Impact factor: 17.388

10.  Identification of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration.

Authors:  Horacio Gomez-Acevedo; Yuemeng Dai; Graham Strub; Carrie Shawber; June K Wu; Gresham T Richter
Journal:  Sci Rep       Date:  2020-02-24       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.